ALL-REMOTE COMPANY/WILMINGTON, Del. / Aug 12, 2025 / Business Wire / Phreesia, a leader in patient intake, outreach and activation, has been named to the 2025 Capterra Shortlist in the Patient Engagement and Medical Scheduling categories. The Capterra Shortlist is an independent assessment that evaluates user reviews and online search activity to identify a list of market leaders that offer the top products in various software categories.
"Being named to two of the 2025 Capterra Shortlists is an honor that reflects the positive reviews and feedback we receive from our healthcare provider clients,” said Phreesia CEO Chaim Indig. “Our digital solutions help engage and empower patients to take a more active role their care, and this award is a welcome recognition of those efforts.”
Phreesia has an overall rating of 4.3 out of 5 on Capterra, driven by direct feedback from clients. “Phreesia has become an integral partner in the management of my practice. It allows us to focus more on providing quality care to our patients,” one practice director shared in a review on the Capterra site.
Capterra uses exclusive data and trusted reviews from verified software users to build its Capterra Shortlist reports, which present a comprehensive view of products’ recent popularity and ratings based on data from a defined timeframe.
For more information on Phreesia, visit www.phreesia.com.
About Phreesia
Phreesia is the trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024—1 in 7 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.
Last Trade: | US$31.66 |
Daily Change: | -0.89 -2.73 |
Daily Volume: | 677,648 |
Market Cap: | US$1.880B |
May 28, 2025 March 12, 2025 December 09, 2024 October 28, 2024 October 01, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load